{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["123(2)"],"submitter":["Imanaka R"],"funding":["AbbVie GK"],"pubmed_abstract":["Venetoclax (VEN) with azacitidine (AZA) is the standard treatment for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. However, real-world evidence on dosing, scheduling, and outcomes is lacking, particularly for patients with prior myelodysplastic syndrome (MDS) or AZA treatment, who have been excluded from clinical trials. This was a multicenter retrospective study of VEN + AZA in 120 patients newly diagnosed with AML between June 2021 and September 2022. The cohort had a median age of 77 years, 52% had secondary AML, 74% had previously been diagnosed with MDS, and 39% had previously received AZA. During cycle 1, half of the patients received 400 mg of VEN for a median of 27 days, with a median holding period of 12 days. With a median follow-up of"],"journal":["International journal of hematology"],"pagination":["178-188"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12913348"],"repository":["biostudies-literature"],"pubmed_title":["Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study)."],"pmcid":["PMC12913348"],"pubmed_authors":["Ota S","Kosugi-Kanaya M","Katsuoka Y","Imanaka R","Uoshima N","Ando J","Matsuoka A","Goto T","Morita T","Yoshimoto G","Numata H","Hara S","Tsutsui A"],"additional_accession":[]},"is_claimable":false,"name":"Real-world outcomes of venetoclax and azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia (VENUS study).","description":"Venetoclax (VEN) with azacitidine (AZA) is the standard treatment for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. However, real-world evidence on dosing, scheduling, and outcomes is lacking, particularly for patients with prior myelodysplastic syndrome (MDS) or AZA treatment, who have been excluded from clinical trials. This was a multicenter retrospective study of VEN + AZA in 120 patients newly diagnosed with AML between June 2021 and September 2022. The cohort had a median age of 77 years, 52% had secondary AML, 74% had previously been diagnosed with MDS, and 39% had previously received AZA. During cycle 1, half of the patients received 400 mg of VEN for a median of 27 days, with a median holding period of 12 days. With a median follow-up of","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T06:39:07.791Z","creation":"2026-07-09T10:40:13.586Z"},"accession":"S-EPMC12913348","cross_references":{"pubmed":["41201768"],"doi":["10.1007/s12185-025-04093-y"]}}